The anticancer effect of metformin targets VDAC1 via ER-mitochondria interactions-mediated autophagy in HCC
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Metformin (MetF) is used worldwide as a first-line therapy for type 2 diabetes. Recently, interest in the pleiotropic effects of MetF, such as its anticancer and antiaging properties, has increased. However, the molecular target of MetF and the detailed mechanism underlying its ability to inhibit cell growth through autophagy induction remain incompletely understood. In this study, using an innovative label-free drug affinity responsive target stability (DARTS)-LC-MS/MS method, we discovered that mitochondrial voltage-dependent anion channel 1 (VDAC1) is a novel binding protein involved in the induction of autophagy-related cell death by high-dose MetF in hepatocellular carcinoma (HCC). Computational alanine scanning mutagenesis revealed that MetF and VDAC1 (D9, E203) interact electrostatically. MetF disrupts the IP3R-GRP75-VDAC1 complex, which plays a key role in stabilizing mitochondria-associated ER membranes (MAMs), by binding to VDAC1. This disruption leads to increased cytosolic calcium levels, thereby contributing to autophagy induction. MetF also decreased the AMP/ATP ratio and activated the AMPK pathway. Cells with genetic knockdown of VDAC1 mimicked the activity of MetF. In conclusion, this study provides new insights into the involvement of MetF in ionic interactions with VDAC1, contributing to its anticancer effects in HCC. These findings help elucidate the diverse biological and pharmacological effects of MetF, particularly its influence on autophagy, as well as the potential of MetF as a therapeutic agent for diseases characterized by VDAC1 overexpression.
Abstract
Metformin (MetF) is used worldwide as a first-line therapy for type 2 diabetes. Recently, interest in the pleiotropic effects of MetF, such as its anticancer and antiaging properties, has increased. However, the molecular target of MetF and the detailed mechanism underlying its ability to inhibit cell growth through autophagy induction remain incompletely understood. In this study, using an innovative label-free drug affinity responsive target stability (DARTS)-LC-MS/MS method, we discovered that mitochondrial voltage-dependent anion channel 1 (VDAC1) is a novel binding protein involved in the induction of autophagy-related cell death by high-dose MetF in hepatocellular carcinoma (HCC). Computational alanine scanning mutagenesis revealed that MetF and VDAC1 (D9, E203) interact electrostatically. MetF disrupts the IP3R-GRP75-VDAC1 complex, which plays a key role in stabilizing mitochondria-associated ER membranes (MAMs), by binding to VDAC1. This disruption leads to increased cytosolic calcium levels, thereby contributing to autophagy induction. MetF also decreased the AMP/ATP ratio and activated the AMPK pathway. Cells with genetic knockdown of VDAC1 mimicked the activity of MetF. In conclusion, this study provides new insights into the involvement of MetF in ionic interactions with VDAC1, contributing to its anticancer effects in HCC. These findings help elucidate the diverse biological and pharmacological effects of MetF, particularly its influence on autophagy, as well as the potential of MetF as a therapeutic agent for diseases characterized by VDAC1 overexpression.
참고문헌 (42)
- Foretz, M., "Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus", Nat. Rev. Endocrinol, 15, pp.569~589 (2019)
- Wang, Y. -W., "Metformin : a review of its potential indications", Drug Des. Devel Ther, 11, pp.2421~2429 (2017)
- Zhang, Z. -J., "Metformin for liver cancer prevention in patients with type 2diabetes : a systematic review and meta-analysis", J. Clin. Endocrinol. Metab, 97, pp.2347~2353 (2012)
- Owen, M. R., "Evidence that metformin exerts its antidiabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain", Biochem. J, 348, pp.607~614 (2000)
- Yu, R., "Berberine-induced apoptotic and autophagic death of HepG2 cells requires AMPK activation", Cancer Cell Int, 14, pp.1~8 (2014)
- Hu, M., "AZD8055 induces cell death associated with autophagy and activation of AMPK in hepatocellular carcinoma", Oncol. Rep, 31, pp.649~656 (2014)
- Ma, T., "Low-dose metformin targets the lysosomal AMPK pathway through PEN2", Nature, 603, pp.159~165 (2022)
- Graham, G. G., "Clinical pharmacokinetics of metformin", Clin. Pharmacokinet, 50, pp.81~98 (2011)
- Zeng, Y. C., "Structural basis of promiscuous substrate transport by Organic Cation Transporter 1", Nat. Commun, 14, pp.6374~ (2023)
- Chen, L., "OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin", Proc. Natl Acad. Sci. USA, 111, pp.9983~9988 (2014)
- Michelakis, E. D., "Mitochondrial medicine : a new era in medicine opens new windows and brings new challenges", Circulation, 117, pp.2431~2434 (2008)
- Rena, G., "The mechanisms of action of metformin", Diabetologia, 60, pp.1577~1585 (2017)
- Chang, J., "Advances in identification and validation of protein targets of natural products without chemical modification", Nat. Prod. Rep, 33, pp.719~730 (2016)
- Phillips, M. J., "Structure and function of ER membrane contact sites with other organelles", Nat. Rev. Mol. Cell Biol, 17, pp.69~82 (2016)
- Kerkhofs, M., "Emerging molecular mechanisms in chemotherapy : Ca2+signaling at the mitochondria-associated endoplasmic reticulum membranes", Cell Death Differ, 9, pp.334~ (2018)
- Liu, Y., "DJ-1 regulates the integrity and function of ER-mitochondria association through interaction with IP3R3-Grp75-VDAC1", Proc. Natl Acad. Sci. Usa, 116, pp.25322~25328 (2019)
- An, G., "Relevance of the endoplasmic reticulum-mitochondria axis in cancer diagnosis and therapy", Exp. Mol. Med, 56, pp.40~50 (2024)
- Roos, K., "OPLS3e : Extending force field coverage for drug-like small molecules", J. Chem. Theory Comput, 15, pp.1863~1874 (2019)
- Bochevarov, A. D., "Jaguar : A high-performance quantum chemistry software program with strengths in life and materials sciences", Int J. Quantum Chem, 113, pp.2110~2142 (2013)
- Halgren, T. A., "Identifying and characterizing binding sites and assessing druggability", J. Chem. Inf. Model, 49, pp.377~389 (2009)
- Halgren, T., "New method for fast and accurate binding-site identification and analysis", Chem. Biol. Drug Des, 69, pp.146~148 (2007)
- Deng, Z., "Structural interaction fingerprint(SIFt) : a novel method for analyzing three-dimensional protein-ligand binding interactions", J. Med. Chem, 47, pp.337~344 (2004)
- Lomize, M. A., "OPM : orientations of proteins in membranes database", Bioinformatics, 22, pp.623~625 (2006)
- Jo, S., "CHARMM-GUI: a web-based graphical user interface for CHARMM", J. Comput Chem, 29, pp.1859~1865 (2008)
- Jo, S., "Automated builder and database of protein", membrane complexes for molecular dynamics simulations, 2007, pp.2, e880~
- Weiser, B. P., "Computational investigation of cholesterol binding sites on mitochondrial VDAC", J. Phys. Chem. B, 118, pp.9852~9860 (2014)
- Hwang, H. -Y., "Antidepressant drug sertraline modulates AMPK-MTOR signaling-mediated autophagy via targeting mitochondrial VDAC1 protein", Autophagy, 17, pp.2783~2799 (2021)
- Kim, D., "Activation of mitochondrial TUFM ameliorates metabolic dysregulation through coordinating autophagy induction", Commun. Biol, 4, pp.1~ (2021)
- Hwang, H. -Y., "Autophagic inhibition via lysosomal integrity dysfunction leads to antitumor activity in glioma treatment", Cancers, 12, pp.543~ (2020)
- Kim, D., "FK506, an immunosuppressive drug, induces autophagy by binding to the V-ATPase catalytic subunit A in neuronal cells", J. Proteome Res, 16, pp.55~64 (2017)
- Park, Y., "AMPK-induced mitochondrial biogenesis decelerates retinal pigment epithelial cell degeneration under nutrient starvation", BMB Rep, 56, pp.84~89 (2023)
- Jang, H. -J., "Thrap3 promotes nonalcoholic fatty liver disease by suppressing AMPK-mediated autophagy", Exp. Mol. Med, 55, pp.1720~1733 (2023)
- Gomez-Suaga, P., "The ER-mitochondria tethering complex VAPB-PTPIP51regulates autophagy", Curr. Biol, 27, pp.371~385 (2017)
- Nguyen, H. T., "Regulation of autophagy by perilysosomal calcium: a new player in β-cell lipotoxicity", Exp. Mol. Med, 56, pp.273~288 (2024)
- Kim, E. -K., "Metformin ameliorates experimental-obesity-associated autoimmune arthritis by inducing FGF21 expression and brown adipocyte differentiation", Exp. Mol. Med, 50, pp.e432~ (2018)
- Cunha, V., "Metformin in the prevention of hepatocellular carcinoma in diabetic patients: a systematic review", Ann. Hepatol, 19, pp.232~237 (2020)
- Kulkarni, A. S., "Benefits of metformin in attenuating the hallmarks of aging", Cell Metab, 32, pp.15~30 (2020)
- Triggle, C. R., "Metformin: Is it a drug for all reasons and diseases?", Metabolism, 133, pp.155223~ (2022)
- Horiuchi, T., "Metformin directly binds the alarmin HMGB1 and inhibits its proinflammatory activity", J. Biol. Chem, 292, pp.8436~8446 (2017)
- Wu, N. N., "Site-specific ubiquitination of VDAC1 restricts its oligomerization and mitochondrial DNA release in liver fibrosis", Exp. Mol. Med, 55, pp.269~280 (2023)
- Hwang, M. -S., "Tschimganidine reduces lipid accumulation through AMPK activation and alleviates high-fat dietinduced metabolic diseases", BMB Rep, 56, pp.246~251 (2023)
- Entezari, M., "AMPK signaling in diabetes mellitus, insulin resistance and diabetic complications : A pre-clinical and clinical investigation", Biomed. Pharmacother, 146, pp.112563~ (2022)